Name | Lirilumab |
---|
Description | Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2]. |
---|---|
Related Catalog | |
In Vivo | Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2]. Animal Model: Rag1KO-Tg KIR mice injected with tumor cells[2] Dosage: 15 mg/kg Administration: intravenous injection; 15 mg/kg; once Result: Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died. |
References |
No Any Chemical & Physical Properties |